Clinical Oncology - Issue 2/2024
Editorial
Reviews
T. Urban, P. Pokorná, O. Slabý
A. A. Soror, R. Eshagh, M. R. Fahim, A. Jamshidian, G. H. Monfared
M. Švecová, K. Fiedlerová, M. Mareková, K. Dubayová
Original Articles
J. Fínek, M. Vočka, J. Bauer, E. Kubala, K. Zycháčková, M. Šedivá, M. Gharibyar, I. Kocáková, E. Čmuchařová, M. Vaňková
M. Homolová, E. Bojtárová, M. Kováčová, K. Klučková, M. Suchánková, M. Kušíková, M. Mistrík, I. Shawkatová
P. Sorokin, M. Novozhilov, D. Utkin, Z. Abduragimova, I. Dudina, A. Nikiforchin, S. Kulikova
Case Reports
I. Šimková, R. Aiglová, F. Koubek, J. Přeček, J. Látal, E. Buriánková, L. Quinn, L. Henzlová, M. Táborský, H. Švébišová, L. Tučková, B. Melichar
Reports from the literature
Various
Clinical Oncology
2024 Issue 2
Most read in this issue
- Feasibility of implementation of the early tumor shrinkage as a potential predictive marker to daily clinical practice in patients with RAS wild type metastatic colorectal cancer, treated with cetuximab – a non-interventional observational study
- Editorial
- Significance of aberrant DNA methylation for cancer diagnostics and therapy
- Factors influencing overall survival and GvHD development after allogeneic hematopoietic stem cell transplantation – single centre experience